Phytochemistry Reviews

, Volume 4, Issue 1, pp 11–18 | Cite as

Cannabinoids in Models of Chronic Inflammatory Conditions

  • Raphael Mechoulam
  • Percy F. Sumariwalla
  • Marc Feldmann
  • Ruth Gallily
Open Access
Article

Abstract

Cannabis sativa has been used as an anti-inflammatory plant for millennia. However until the elucidation of the chemistry of its constituents and the discovery of the endogenous cannabinoid system only a limited amount of research had been done on the effects of the plant or its constituents on inflammation. In the present overview we summarize our work on the effects of the non-psychotropic cannabidiol (CBD) and of a synthetic cannabidiol-derived acid (HU-320) in animal models of arthritis. Both compounds block progression of the disease, when administered after its onset. Cannabidiol was equally effective was administered i.p. or orally. Significant protection of the joints against severe damage was noted. In vitro cannabidiol reduced lymphocyte proliferation, and TNF-α formation and blocked zymosan-triggered production of reactive oxygen intermediates (ROI). Ex vivo lymph node cells from CBD-treated mice showed a decrease of collagen II-specific proliferation and IFN-γ production. A decreased release of TNF by knee synovial cells was also noted. A synthetic cannabidiol derivative, HU-320 also inhibited production of TNF and ROI by mouse macrophages in vitro and suppressed in vivo rise in serum TNF following endotoxin challenge. HU-320 showed no activity in a standard assay for THC-type psychotropic effects. These results suggest that CBD and HU-320 hold promise as potential novel anti-inflammatory agents.

Keywords

cannabidiol HU-320 murine collagen-induced arthritis rheumatoid arthritis TNF-α 

Abbreviations

2-AG

2-arachidonoylglycerol

CBD

cannabidiol

CIA

collagen-induced arthritis

CII

collagen type II

IFN

interferon

IL

interleukin

LPS

lipopolysaccharide

NO

nitric oxide

ROI

reactive oxygen intermediates

THC

tetrahydrocannabinol

TNF

tumor necrosis factor

References

  1. Adams, R 1941–1942MarihuanaHarvey Lect37168197Google Scholar
  2. Agurell, S, Halldin, M, Lingren, JE, Ohlsson, A, Widman, M, Gillespie, H, Hollister, L 1986Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on manPharmacol. Revs382143Google Scholar
  3. Brunner, TF 1973Marijuana in ancient Greece and Rome? The literary evidenceBull. Hist. Med47344355PubMedGoogle Scholar
  4. Burstein S (1989) Delta-1-THC-7-oic Acid and Analgetic and Anti-inflammatory Agents. US Patent 4,847,290Google Scholar
  5. Burstein, SH, Audette, CA, Breuer, A, Devane, WA, Colodner, S, Doyle, SA, Mechoulam, R 1992Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic and leukocyte anti-adhesion activitiesJ. Med. Chem3531353141CrossRefPubMedGoogle Scholar
  6. Burstein,  2001Ajulemic acid.Drugs Future26342345CrossRefGoogle Scholar
  7. Burstein, S 2001

    Therapeutic potential of ajulemic acid (CT3)

    Grotenherman, FRusso, E. eds. Cannabis and CannabinoidsHaworth PressNew York381388
    Google Scholar
  8. Cabral, GA, Harmon, KN, Carlisle, SJ 2001Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: Evidence for CB1 receptor participationAdv. Exp. Med. Biol493207214PubMedGoogle Scholar
  9. Campbell Thompson, R 1949A Dictionary of Assyrian BotanyThe British AcademyLondon220222Google Scholar
  10. Chopra, IC, Chopra, RN 1957The use of cannabis drugs in IndiaBull. Narc9429Google Scholar
  11. Christison, A 1851On the natural history, action and uses of Indian hempMonthly J. Med. Sci132645and 177–121Google Scholar
  12. Dajani, EZ, Larsen, KR, Taylor, J, Dajani, NE, Shahwan, TG, Neeleman, SD, Taylor, MS, Dayton, MT, Mir, GN 19991,1-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: A novel orally effective cannabinoid with analgesic and anti-inflammatory propertiesJ. Pharmacol. Exp. Ther2913138PubMedGoogle Scholar
  13. Devane, WA, Dysarz, FA,3rd, Johnson, MR, Melvin, LS, Howlett, AC 1988Determination and characterization of a cannabinoid receptor in rat brainMol. Pharmacol 34605613PubMedGoogle Scholar
  14. Devane, WA, Breuer, A, Sheskin, T, Jarbe, TUC, Eisen, M, Mechoulam, R 1992aA novel probe for the cannabinoid receptorJ. Med. Chem3520652069CrossRefGoogle Scholar
  15. Devane, WA, Hanus, L, Breuer, A, Pertwee, RG, Stevenson, LA, Griffm, G, Gibson, D, Mandelbaum, A, Etinger, A, Mechoulam, R 1992bIsolation and structure of a brain constituent that binds to the cannabinoid receptorScience25819461949Google Scholar
  16. Dioscorides (1934) The Greek Herbal. In: Gunther RT, (ed) Oxford University Press, pp. 390–391, plant drawings 165 and 166Google Scholar
  17. Donovan, M 1845On the physical and medicinal qualities of Indian hemp (Cannabis indica)Dublin J. Med. Sci26368402and 459–461Google Scholar
  18. Formukong, EA, Evans, AT, Evans, FJ 1988Analgesic and anti-inflammatory activity of constituents of Cannabis sativa LInflammation12361371CrossRefPubMedGoogle Scholar
  19. Fride, E, Mechoulam, R 1993Pharmacological activity of the cannabinoid agonist anandamide, a brain constituentEur. J. Pharmacol231313314CrossRefPubMedGoogle Scholar
  20. Gaoni, Y, Mechoulam, R 1964Isolation structure and partial synthesis of active constituent of hashishJ. Amer. Chern. Soc8616461647CrossRefGoogle Scholar
  21. Hampson, AJ, Grimaldi, M, Axelrod, J, Wink, D 1998Cannabidiol and (-)delta(9)-tetrahydrocannabinol are neuroprotective antioxidantsProc. Natl. Acad. Sci. (USA) 9582688273CrossRefGoogle Scholar
  22. Howlett, AC, Fleming, RM 1984Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranesMol. Pharmacol26532538PubMedGoogle Scholar
  23. Howlett, AC, Champion, TM, Wilken, GH, Mechoulam, R 1990Stereochemical effects of 11-OH-delta-8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptorNeuropharmacol 291161165CrossRefGoogle Scholar
  24. Howlett, AC, Barth, F, Bonner, TI, Cabral, G, Casellas, P, Devane, WA, Felder, CC, Herkenham, M, Mackie, K, Martin, BR, Mechoulam, R, Pertwee, RG 2002lnternation Union of Pharmacology. XXVII. Classification of cannabinoid receptorsPharmacol. Rev54161202CrossRefPubMedGoogle Scholar
  25. Klein, TW, Newton, C, Larsen, K, Lu, L, Perkins, I, Nong, L, Friedman, H 2003The cannabinoid system and immune modulationJ. Leukoc. Biol74486489CrossRefPubMedGoogle Scholar
  26. Lambert, DM, Vandevoorde, S, Jonsson, KO, Fowler, CJ 2002The palmitoylethanolamide family: A new class of anti-inflammatory agents?Curr. Med. Chem9663674PubMedGoogle Scholar
  27. Malfait, AM, Gallily, R, Sumariwalla, PF, Malik, AS, Andreakos, E, Mechoulam, R, Feldmann, M 2000The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritisProc. Natl. Acad. Sci. (USA)9795619566CrossRefGoogle Scholar
  28. Matsuda, LA, Lolait, SJ, Brownstein, MJ, Young, AC, Bonner, TI 1990Structure of a cannabinoid receptor and functional expression of the cloned cDNANature346561564CrossRefPubMedGoogle Scholar
  29. Mechoulam R, Gaoni Y (1967) The absolute configuration of Δ1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahededron Lett. 1109–1111Google Scholar
  30. Mechoulam, R 1970Marihuana chemistryReview. Science16811591166Google Scholar
  31. Mechoulam, R, Ben-Zvi, Z, Agurell, S, Nilsson, IM, Nilsson, JLG, Edery, H, Grunfeld, Y 1973Delta-6-tetrahydrocannabinol-7-oic acid, a urinary delta-6-THC metabolite – isolation and synthesisExperientia2911931195CrossRefPubMedGoogle Scholar
  32. Mechoulam, R. 1986

    The Pharmacohistory of Cannabis sativa

    Mechoulam, R eds. Cannabinoids as Therapeutic AgentsCRC Press, IncBoca Raton Fl119
    Google Scholar
  33. Mechoulam, R, Feigenbaum, JJ, Lander, N, Segal, M, Jarbe, TUC, Hiltunen, AJ, Consroe, P 1988Enantiomeric cannabinoids: Stereospecificity of psychotropic activityExperientia44762764PubMedGoogle Scholar
  34. Mechoulam, R, Ben-Shabat, S, Hanus, L, Ligumsky, M, Kaminski, NE, Schatz, AR, Gopher, A, Almog, S, Martin, BR, Compton, DR 1995Identification of a andogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptorsBiochem. Pharmacol508390CrossRefPubMedGoogle Scholar
  35. Mechoulam, R, Ben-Shabat, S 1999From gan-zi-gun-nu to anandamide and 2-arachidonoyl-glycerol, the ongoing story of CannabisNat. Prod. Rep16131143CrossRefPubMedGoogle Scholar
  36. Mechoulam, R, Hanus, L. 2002Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical AspectsChem. Phys. Lipids1213543CrossRefPubMedGoogle Scholar
  37. Mechoulam, R, Parker, LA, Gallily, R 2002Cannabidiol: An overview of some pharmacological aspectsJ. Clin. Pharmacol4211S19SPubMedGoogle Scholar
  38. Melck, D, Bisogno, T, De-Petrocellis, L, Beaulieu, P, Rice, AS, Di Marzo, V 2002Cannabimimetic eicosanoids in cancer and inflammation: an updateAdv. Exp. Med. Biol507381386PubMedGoogle Scholar
  39. Munro, S, Thomas, KL, Abu-Shaar, M 1993Molecular characterization of a peripheral receptor for cannabinoidsNature3656165CrossRefPubMedGoogle Scholar
  40. O’Shaugnessy WB (1843) On the preparations of the Indian hemp, or Gunjah. Trans. Med. Physical Soc. Bengal, 421–461Google Scholar
  41. Rhee, MH, Vogel, Z, Barg, J, Bayewitch, M, Levy, R, Hanus, L, Breuer, A, Mechoulam, R 1997Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclaseJ. Med. Chem4032283233CrossRefPubMedGoogle Scholar
  42. Rosenkrantz H, Fleischman RW, Grant RJ (1981) Toxicity of short-term administration of cannabinoids to rhesus monkeys. Toxicol. ApGoogle Scholar
  43. Roth, MD, Baldwin, GC, Tashkin, DP 2002Effects of delta-9-tetrahydrocannabinol on human immune function and host defenseChem. Phys. Lipids121229239CrossRefPubMedGoogle Scholar
  44. Russel Reynolds, J 1890Therapeutic uses and toxic effects of Cannabis indicaLancet1637638CrossRefGoogle Scholar
  45. Sancho, R, Calzado, MA, Di Marzo, V, Appendino, G, Munoz, E 2003Anandamide inhibits nuclear factor-KB activation through a cannabinoid receptor-independent pathwayMol. Pharmacol63429438CrossRefPubMedGoogle Scholar
  46. Srivastava, MD, Srivastava, BI, Brouhard, B 1998Delta- 9-tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cellsImmunopharmacol401791885CrossRefGoogle Scholar
  47. Sugiura, T, Kondo, S, Sukagawa, A, Nakane, S, Shinoda, A, Itoh, K, Yamashita, A, Waku, K 19952-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brainBiochem. Biophys. Res. Commun2158997CrossRefPubMedGoogle Scholar
  48. Sulcova, E, Mechoulam, R, Fride, E 1998Biphasic effects ofanandamidePharmacol. Biochem. Behav59347353CrossRefPubMedGoogle Scholar
  49. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M (2004) A novel synthetic non-psychoactive cannabinoid acid (HU-320) with anti-inflammatory properties in murine collagen-induced arthritis. Arthritis Rheumat. (in press)Google Scholar
  50. Todd, AR 1946HashishExperientia25560Google Scholar
  51. Turner, CE, Elsohly, MA, Boeren, EG 1980Constituents of Cannabis sativa L. XVII. A review of the natural constituentsJ. Nat. Prod43169234CrossRefPubMedGoogle Scholar
  52. Watzl, B, Scuderi, P, Watson, RR 1991Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitroInt. J. Immunopharmacol1310911097PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Raphael Mechoulam
    • 1
  • Percy F. Sumariwalla
    • 2
  • Marc Feldmann
    • 2
  • Ruth Gallily
    • 3
  1. 1.Pharmacy School, Medical Faculty, Department of Medicinal Chemistry and Natural ProductsHebrew UniversityJerusalemIsrael
  2. 2.Kennedy Institute of RheumatologyImperial CollegeLondon
  3. 3.The Lauten- berg Center of General and Tumor Immunology, Medical FacultyHebrew UniversityJerusalemIsrael

Personalised recommendations